Long-Term Safety and Effectiveness of Adalimumab for Moderat-to-Severe Psoriasis: Results from the Eight-Year Interim Analysis of the ESPIRIT Registry. J of Skin. 2017;1(3.1):s22. doi:10.25251/skin.1.supp.21